The effect of long-term alendronate treatment on cortical thickness of the proximal femur

Clinical Orthopaedics and Related Research

Volumn 470, Issue 1, 2012, Pages 291-298

  Unnanuntana, Aasis ^a,b   Ashfaq, Kashif ^a   Ton, Quang V ^c   Kleimeyer, John P ^d   Lane, Joseph M ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Englewood Hospital and Medical Center ^*  (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); CORTICAL THICKNESS RATIO; DUAL ENERGY X RAY ABSORPTIOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY MACHINE; FEMALE; FEMUR; FEMUR SHAFT; FOLLOW UP; GREATER TROCHANTER; HUMAN; IMAGING SOFTWARE; LIMIT OF DETECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL DEVICE; MIDDLE AGED; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOPENIA; PICTURE ARCHIVING AND COMMUNICATION SYSTEM; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; BONE DENSITY; CASE CONTROL STUDY; COMPARATIVE STUDY; DENSITOMETRY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMUR FRACTURE; HOSPITALIZATION; METHODOLOGY; PATHOLOGIC FRACTURE; RADIOGRAPHY; REFERENCE VALUE; TIME; TREATMENT FAILURE;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMORAL FRACTURES; FEMUR; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; LONG-TERM CARE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 84858250192     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-011-1985-9     Document Type: Article

References (28)

1. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009;85:37-44.
2. Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom. 2008;11:351-359.
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
4. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189-1199.
5. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010; 25:2558-2571.
6. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-2026.
7. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/ case series studies. Bone. 2010;47:169-180.
8. Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J Orthop Trauma. 2010;24:75-81.
9. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353-1362.
10. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620.
11. Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, Norimatsu H. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005;23 Suppl:36-42.
12. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524- 531.
13. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
14. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
15. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346-350.
16. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual midshaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72:161-168.
17. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
18. Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356:1075-1076.
19. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9:461-468.
20. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of longterm bisphosphonate treatment. Curr Med Res Opin. 2004;20: 1291-1300.
21. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49: 2-19.
22. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25:1886- 1894.
23. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.
24. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14:605- 615.
25. Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92:743- 753.
26. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948-2952.
27. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19: 365-372.
28. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-1565.